Experimental PSP drug shows promise in early trial
NCT ID NCT05819658
First seen Feb 11, 2026 · Last updated May 08, 2026 · Updated 18 times
Summary
This study tested a drug called GV1001 in 78 people with Progressive Supranuclear Palsy (PSP), a rare brain disease that affects movement and thinking. Participants received daily injections of either a low dose, a high dose, or a placebo for 6 months. The goal was to see if the drug could slow the worsening of symptoms, measured by a PSP rating scale.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE SUPRANUCLEAR PALSY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kyung Hee University Hospital
Seoul, South Korea
-
Samsung Medical Center
Seoul, South Korea
-
Seoul Metropolitan Government Seoul National University Boramae Medical Center
Seoul, South Korea
-
Seoul National University Bundang Hospital
Seongnam-si, South Korea
-
Seoul National University Hospital
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.